Mateus Alves Borges Cristino

Mateus Alves Borges Cristino

Auto-generated profile, based on publicly available information

Mateus Alves Borges Cristino

Rede Mater Dei de Saúde

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2021 in REVISTA CIÊNCIAS EM SAÚDE
Verified
Journal Article
Open access
PDF file
MSMelissa Andreia De Moraes Silva
Melissa Andreia De Moraes Silva
MCMateus Alves Borges Cristino
Mateus Alves Borges Cristino
RPRicardo Jayme Procópio
Ricardo Jayme Procópio
Vaccines against COVID-19 from Moderna Biotech Spain, SL (COVID-19 Vaccine Moderna – mRNA technology), AstraZeneca (Oxford/Astrazeneca Vaccine - ChAdOx1 - adenovirus vector technology) and Janssen-Cilag International NV (COVID-19 Vaccine) Janssen - Ad.26.COV2.S - adenovirus vector technology) used in Europe, the United States and Brazil has presented severe thrombotic adverse reactions. The recorded thrombosis occurred in unusual sites, such as the sagittal venous sinus.

27 July 2026 in Journal of Ultrasound
Verified
Journal Article
Open access
PDF file
WLWellington Gianoti Lustre
Wellington Gianoti Lustre
LLLibnah Leal
Libnah Leal
VCVinicius Cardoso
Vinicius Cardoso
MCMateus Aves Borges Cristino
Mateus Aves Borges Cristino
CFCarolina Dutra Queiroz Flumignan
Carolina Dutra Queiroz Flumignan
LNLuis Carlos Uta Nakano
Luis Carlos Uta Nakano
Background: Lifelong imaging surveillance after endovascular aneurysm repair (EVAR) is essential for endoleak detection but is limited by cumulative radiation and nephrotoxicity from computed tomography angiography (CTA). Contrast-enhanced ultrasound (CEUS) has emerged as a promising alternative, although prospective comparative data remain limited. Methods: In this prospective, single-centre diagnostic accuracy study, 30 consecutive patients (mean age 78.5 ± 7.1 years; 70% male) undergoing EVAR follow-up were evaluated with duplex ultrasound (DUS), CEUS (SonoVue®), and CTA within a 30-day interval. CTA served as the reference standard. Diagnostic performance metrics were calculated with 95% confidence intervals (CIs) according to STARD recommendations. Results: Endoleaks were identified in 11 patients (36.7%). CTA detected 8 cases (26.7%), CEUS 9 (30.0%), and DUS 4 (13.3%). CEUS demonstrated high sensitivity (87.5%; 95% CI 47.3–99.7%) and specificity (90.9%; 70.8–98.9%), with overall accuracy of 90.0% (73.5–97.9%). In contrast, DUS showed limited sensitivity (33.3%; 9.9–65.1%) despite perfect specificity (100%), yielding lower accuracy (73.3%). Inter-modality agreement was 83.3%. Conclusions: CEUS demonstrates high diagnostic accuracy for endoleak detection after EVAR and represents a robust, radiation-free alternative to CTA for longitudinal surveillance. Given its favourable safety profile and diagnostic performance, CEUS should be considered a first-line imaging modality in routine follow-up, with CTA reserved for equivocal findings or pre-interventional planning. These results support a paradigm shift toward CEUS-based surveillance strategies.

1 January 2026 in Jornal Vascular Brasileiro
Verified
Journal Article
Open access
MCMateus Alves Borges Cristino
Mateus Alves Borges Cristino
RFRonald Luiz Gomes Flumignam
Ronald Luiz Gomes Flumignam
GMGustavo Braga Murta
Gustavo Braga Murta
Marcos Arêas MarquesMarcos Arêas Marques
Marcos Arêas Marques
Resumo A embolia pulmonar é a principal causa de morte materna durante o ciclo gravídico-puerperal em países desenvolvidos. O diagnóstico do tromboembolismo venoso na gravidez é dificultado pelas mudanças fisiológicas que ocorrem na gestação. O tratamento com anticoagulantes é a abordagem de escolha, sendo intervenções endovasculares procedimentos de exceção. Relatamos um caso de implante de filtro de veia cava inferior removível em gestante com trombose venosa ilíaco-femoral esquerda em período de parto latente. Após o parto, o filtro de veia cava inferior foi removido com sucesso, sem complicações maternas ou fetais, e a anticoagulação foi retomada. Considerando os riscos associados ao filtro de veia cava inferior em gestantes, seu uso deve ser restrito a casos com contraindicações formais à anticoagulação e alto risco de embolia pulmonar. Precauções adicionais minimizam a exposição fetal à radiação. A decisão pelo filtro de veia cava inferior na gravidez é complexa, requer discussão interdisciplinar e, além disso, pesquisas adicionais são necessárias para avaliar seu impacto.

1 January 2026 in Jornal Vascular Brasileiro
Verified
Journal Article
Open access
MCMateus Alves Borges Cristino
Mateus Alves Borges Cristino
RFRonald Luiz Gomes Flumignam
Ronald Luiz Gomes Flumignam
GMGustavo Braga Murta
Gustavo Braga Murta
Marcos Arêas MarquesMarcos Arêas Marques
Marcos Arêas Marques
Pulmonary embolism (PE) is the leading cause of maternal death during the antepartum-postpartum cycle in developed countries. The diagnosis of venous thromboembolism during pregnancy is complicated by the physiological changes that occur during gestation. Management with anticoagulants is the treatment of choice, while endovascular interventions are reserved for exceptional cases. We report a case of placement of a removable inferior vena cava filter (IVCF) in a pregnant woman with left iliofemoral venous thrombosis during latent labor. After delivery, the IVCF was successfully removed with no maternal or fetal complications and anticoagulation was resumed. Considering the risks associated with IVCFs in pregnant women, their use should be restricted to cases with formal contraindications to anticoagulation and high risk of PE. Additional precautions minimize fetal radiation exposure. The decision to place an IVCF during pregnancy is complex and requires interdisciplinary discussion. Further research is needed to assess its impact.